A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 6,312 shares of ASND stock, worth $858,936. This represents 0.05% of its overall portfolio holdings.

Number of Shares
6,312
Previous 6,975 9.51%
Holding current value
$858,936
Previous $951,000 0.95%
% of portfolio
0.05%
Previous 0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 22, 2024

SELL
$113.0 - $153.43 $74,919 - $101,724
-663 Reduced 9.51%
6,312 $942,000
Q2 2024

Jul 19, 2024

SELL
$121.07 - $153.67 $7,143 - $9,066
-59 Reduced 0.84%
6,975 $951,000
Q1 2024

Apr 17, 2024

BUY
$123.45 - $159.4 $108,882 - $140,590
882 Added 14.34%
7,034 $1.06 Million
Q4 2023

Jan 10, 2024

SELL
$86.1 - $127.36 $7,404 - $10,952
-86 Reduced 1.38%
6,152 $774,000
Q3 2023

Oct 27, 2023

BUY
$86.5 - $103.97 $38,752 - $46,578
448 Added 7.74%
6,238 $584,000
Q2 2023

Aug 09, 2023

BUY
$69.96 - $97.84 $8,115 - $11,349
116 Added 2.04%
5,790 $517,000
Q1 2023

Apr 20, 2023

BUY
$104.9 - $126.78 $101,123 - $122,215
964 Added 20.47%
5,674 $608,000
Q4 2022

Jan 12, 2023

BUY
$99.42 - $131.97 $468,268 - $621,578
4,710 New
4,710 $575,000
Q2 2022

Jul 19, 2022

SELL
$78.08 - $117.61 $964,366 - $1.45 Million
-12,351 Closed
0 $0
Q1 2022

Apr 26, 2022

SELL
$102.18 - $135.75 $63,555 - $84,436
-622 Reduced 4.79%
12,351 $1.45 Million
Q4 2021

Feb 14, 2022

SELL
$127.1 - $169.66 $1.47 Million - $1.96 Million
-11,545 Reduced 47.09%
12,973 $1.75 Million
Q3 2021

Nov 12, 2021

SELL
$112.67 - $176.92 $130,133 - $204,342
-1,155 Reduced 4.5%
24,518 $3.91 Million
Q2 2021

Aug 13, 2021

BUY
$121.62 - $145.29 $76,134 - $90,951
626 Added 2.5%
25,673 $3.38 Million
Q1 2021

May 17, 2021

BUY
$124.92 - $173.33 $3.13 Million - $4.34 Million
25,047 New
25,047 $3.23 Million

Others Institutions Holding ASND

About Ascendis Pharma A/S


  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.59B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track This Portfolio

Track Hennion & Walsh Asset Management, Inc. Portfolio

Follow Hennion & Walsh Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.